Remove Business Development Remove DNA Remove Drug Delivery
article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry.

article thumbnail

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

The Pharma Data

LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. In addition to mRNA, Acuitas LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA.